Cashu
Ultragenyx Faces Class Action Lawsuits After Phase 3 Trial Failures and Investor Discontent
2 days ago
Stocks
Health Care
rare
Ultragenyx Pharmaceutical
NASDAQ: RARE
-0.27 (-1.25%)
21.795
USD
At close at Mar 04, 21:38 UTC
Latest Ultragenyx Pharmaceutical News
prnewswire.com
Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RGRD Law
about 10 hours ago
prnewswire.com
LEVI & KORSINSKY, LLP: RARE STOCK DECLINED OVER 42% FOLLOWING PHASE III STUDY FAILURE DISCLOSURE
about 17 hours ago
cnbc.com
'In a bit of chaos': FDA watchers warn about agency hemorrhaging staff and the risk to America's health
1 day ago
prnewswire.com
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit
1 day ago
prnewswire.com
Shareholders that lost money on Ultragenyx Pharmaceutical Inc.(RARE) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
1 day ago
prnewswire.com
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
3 days ago
prnewswire.com
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE
3 days ago
prnewswire.com
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
5 days ago
prnewswire.com
RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
6 days ago
prnewswire.com
Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RARE
6 days ago
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.